Acta Scientific Pharmaceutical Sciences (ASPS)(ISSN: 2581-5423)

Commentary Volume 6 Issue 1

Should We Routinely Use Ivermectin to Treat Covid-19 in Early Stage?

Tapan K Chaudhuri* and Paul E Marik

Professor, Hampton, Virginia and Virginia Beach, Virginia, USA

*Corresponding Author: Tapan K Chaudhuri, Professor, Hampton, Virginia, USA.

Received: November 27, 2021; Published: December 07, 2021

The FDA/CDC/NIH/WHO‘s negative campaign of labeling Ivermectin (IVM) as the drug for horses appears paradoxixal because FDA had already approved IVM for use in human too for de-worming, river blindness and Scabies without any concern for any side effects. Then why does FDA have concern for side effects of IVM when used for COVID-19?

References

  1. Caly L., et al. “The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro”. Antivirus Research April 3, (2020): 104787.
  2. Santin AD., et al. “Ivermectin: a multifaceted drug of Nobel prize-honoured distinction with indicated efficacy against a new global scourge, COVID-19”. New Microbes and New Infections 43 (2021): 100924.
  3. Henrique Pott-Junior., et al. “Use of Ivermectin in the treatment of COVID-19: A pilot trial”. Toxicology Reports 8 (2020): 505-510.
  4. Padhy BM., et al. “Therapeutic potential of ivermectin as add on treatment in COVID-19: a systematic review and meta-analysis”. Journal of Pharmaceutical Sciences 23 (2020): 462-469.
  5. Ahmed S., et al. “A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness”. International Journal of Infectious Diseases 103 (2020): 214-216.
  6. Rajter JC., et al. “Use of ivermectin is associated with lower mortality in hospitalized patients with COVID-19: the ICON study”. Chest 13 (2020): 1016.
  7. Khan Sharun., et al. “Ivermectin, a new candidate therapeutic against SARS-CoV-2/COVID-19"”. Annals of Clinical Microbiology and Antimicrobials 19.1 (2020): 23.
  8. Chaudhuri TK and Richard Hoffler. “Early Therapeutic Intervention in COVID-19 Infection May Prevent Death”. Acta Scientific Pharmaceutical Sciences1 (2021): 94.
  9. Alam MT., et al. “A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline”. Journal of Bangladesh College of Physicians and Surgeons 38 (COVID-19 Supplement Issue) July (2020): 10-15.

Citation

Citation: Tapan K Chaudhuri and Paul E Marik. “Should We Routinely Use Ivermectin to Treat Covid-19 in Early Stage?". Acta Scientific Pharmaceutical Sciences 6.1 (2022): 13-14.

Copyright

Copyright: © 2022 Tapan K Chaudhuri and Paul E Marik. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate32%
Acceptance to publication20-30 days

Indexed In




News and Events


  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is December 15, 2022.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of “Best Article of the Issue”.
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.
  • Contact US